← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #684 OF 1,000 MOST-CITED

Drug product label, outsourcer facility

FDA cited this observation 30 times across 25 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs30
BY FISCAL YEAR
FY20226
FY20211
FY20201
FY20195
FY20184
FY20179
FY20164

How FDA worded it — real examples

The labels of your outsourcing facility's drug products are deficient.

Qualgen, LLC · Edmond, Oklahoma · Drugs · 2022-09-30

The labels of your outsourcing facility's drug products are deficient.

Empower Clinic Services LLC · Houston, Texas · Drugs · 2022-08-05

The labels of your outsourcing facility's drug products are deficient.

FARMAKEIO OUTSOURCING LLC · Southlake, Texas · Drugs · 2022-06-10

The labels of your outsourcing facility's drug products are deficient.

New England Life Care, Inc. dba Advanced Compounding Solutions · Woburn, Massachusetts · Drugs · 2022-04-28

The labels of your outsourcing facility's drug products are deficient.

US Specialty Formulations LLC · Allentown, Pennsylvania · Drugs · 2022-04-26

The labels of your outsourcing facility's drug products are deficient.

Edge Pharma, LLC · Colchester, Vermont · Drugs · 2021-11-30

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →